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Abstract
Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers 
differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) 
expression on various types of leukemia has been well studied. Here, the role and expression of 
LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is 
reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic 
peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric 
nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 
expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a 
differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. 
Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease 
hold promise as a selective drug delivery system for leukemia treatment.
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FUNCTION OF LFA-1 AND ITS ROLE IN DISEASES
Leukocyte function associated antigen-1 (LFA-1) is a heterodimeric protein comprised of 
alpha (Mw = 180 kDa) and beta (Mw = 95 kDa) subunits. It is a member of the integrin 
family constitutively expressed on all immune cell subsets including leukocytes (1–4). 
LFA-1 plays a role in many immunological response processes including adhesion and 
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transmigration of leukocytes through endothelium and participates in the immunological 
synapse between T cells and antigen presenting cells in T cell activation (2, 5). The 
activation of T cells can induce proliferation and differentiation of T cells (2, 6). The major 
binding ligand of LFA-1 is intercellular adhesion molecule-1 (ICAM-1)(7). LFA-1 
activation is tightly regulated through intracellular signaling (inside-out signaling) and it is a 
prerequisite for ligand binding (2). The binding of LFA-1 to its ligand triggers intracellular 
signaling leading to conformational change of LFA-1 from a low affinity to a high affinity 
form which has a greater accessibility to its ligand and allows tighter binding(2). In addition 
to the high affinity conformation, the binding of LFA-1 to its ligand may also be enhanced 
by clustering of LFA-1 (2, 8). The cluster formation is initiated by multivalent binding of 
LFA-1 to ICAM-1, hence strengthening cell-cell adhesion.
The interaction between LFA-1 and ICAM-1 plays an important role in the regulation of a 
variety of immune responses(9). LFA-1 is important for leukocyte endothelial adhesion and 
extravasation to inflammatory sites. It also plays a key role in co-stimulation required for T 
cell activation. Accordingly, the functions of LFA-1 are relevant to most immunological 
diseases or symptoms such as inflammation, autoimmune diseases and graft rejection after 
organ transplantation (1, 10). The diseases are often typified by overexpression or deficiency 
of LFA-1. Several molecules including antibodies, peptides and small molecules have been 
developed to block the binding of LFA-1 and ICAM-1 (10). Efalizumab(Raptiva®), a 
recombinant anti-human LFA-1 antibody was a prescribed medication used as an 
immunosuppressive agent in psoriasis (11). However, Raptiva® has been associated with an 
increased risk of progressive leukoencephalopathy(PML) which is a fatal disease of the 
central nervous system, therefore; it was withdrawn from the market in mid-2009 (12). Both 
monotherapy of anti-LFA-1 and combination therapy with anti-ICAM-1 antibody were 
effective in promoting long-term survival of islet, cardiac, small bowel and nerve allografts 
in animal models (1, 13–17). Treatment with anti-LFA-1 antibodies has shown disease 
prevention in animal models with autoimmune encephalomyelitis and autoimmune diabetes 
and has shown benefits in lupus and inflammatory arthritis (1, 18–22).
LEUKEMIA AND TARGETED DRUG DELIVERY
Leukemia is a malignant disease originating in the bone marrow. An abnormal proliferation 
of blood cells leads to an excess of these cells entering the blood stream (23). Leukemia has 
a higher mortality rate than other types of cancer among children and young adults under the 
age of 20 (24). Currently, most forms of leukemia are treated with pharmaceuticals, 
typically by combination chemotherapy regimens. Patients may also be treated with 
radiation therapy or bone marrow transplantation, however, these treatments are generally 
more invasive(25). Drug discovery for treating leukemia is focused on enhancing efficacy, 
while minimizing therapy-related toxicity. A promising therapeutic strategy is selective 
targeting of molecular markers of malignant cells, which are not expressed or are expressed 
to a lesser extent on normal human hematopoietic stem cells or lymphocytes (25).
Progress in therapeutic interventions leading to improved disease outcomes is primarily a 
result of the continued development of improved anticancer drugs. The effectiveness of 
these drugs is linked to the capability to selectively target cancer cells while minimizing 
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toxicity to normal cells. As a result, specifically targeting potent drugs to cancer cells is a 
key to successful treatment of leukemia. There are various agents that have been 
investigated for targeted therapy including monoclonal antibodies against cell surface 
antigens, kinase inhibitors, signaling molecule inhibitors, and proteasome inhibitors (25). 
The use of antibodies for leukemic cell-targeted delivery of potent cytotoxic agents such as 
calicheamicin has also been investigated to overcome the dose limitations imposed by the 
side effects of non-targeted therapeutics (26).
Several targeted molecules are currently under intense investigation. CD33 is a glycoprotein 
up-regulated on normal myeloid cells during differentiation, which is expressed on the 
surface of leukemia cells in 85–90% of patients with acute myeloid leukemia(AML)(25, 27). 
Anti-CD33 antibody conjugated to calicheamicin has demonstrated response rates of 30–
35% in adults and children with relapsed or primary refractory AML (25, 27). CD22 is a B-
lymphoid lineage-specific glycoprotein that is highly expressed in B-cell lymphomas and B-
precursor acute lymphoblastic leukemia(ALL)(25–26, 28). A CD22-specific 
immunoconjugate of calicheamicin has demonstrated preferential cytotoxic effects against 
CD22+ tumor targets and is more potent than that of unconjugated calicheamicin against 
CD22+ malignant cells (26). BCR-ABL kinase inhibitors (Imatinib and Dasatinib) were 
developed as highly specific small molecules for targeted therapy (29). Imatinib has potent 
clinical activity in chronic lymphoblastic leukemia, however, the response was short-lived 
(2–3 months) and some patients relapsed due to resistance to the drug (25, 29). The new 
class ABL/Src kinase inhibitor, Dasatinib, could potentially improve the activity of Imatinib. 
Dasatinib is highly effective as a single agent for patients with Imatinib-resistant chronic 
myelogenous leukemia(CML) with minimal side effects (25). Other targeted therapies 
include the inhibition of FMS-like tyrosine kinase 3(FLT3) which is expressed in more than 
90% of AML patients (30). This proteasome inhibitor is part of a new class of drugs 
inhibiting the degradation of NF-κB, a transcriptional activator known to have anti-apoptotic 
activity. Mammalian Target of Rapamycin Complex-1 (mTOR), a serine/threonine kinase 
regulating cell growth, has been reported in more than 70% of AML patients (25). Inhibition 
of mTOR may be a useful therapeutic strategy for relapsed/refractory AML and ALL in 
children (25).
Actively targeting drugs using a drug carrier (e.g. polymer nanoparticle, liposome, 
dendrimer) may also differentially transport the therapeutically active molecule to the target 
cell. Molecular markers that are either uniquely expressed or overexpressed on leukemic 
cells may allow drugs or drug carriers to bind based on molecular recognition such as 
ligand-receptor or antigen-antibody interactions (30). On leukemic cells, several potential 
targets for drug carriers have emerged. For example, a current clinical trial is evaluating a 
peptide vaccination targeting different epitopes of the Wilms’ tumor gene 1 (WT1), the 
proteinase-3 derived epitope peptide (PR1), and the receptor for hyaluronic acid mediated 
motility (RHAMM/CD168) derived epitope R3 (30). Herceptin® was approved for women 
with breast cancer whose tumors have high level ofHER2 protein is the example of actively 
targeting drugs. Clinical experience with Herceptin® for the adjuvant treatment of HER2+ 
breast cancer began in 2000. In 2006, Herceptin® was approved for the adjuvant treatment 
of HER2+ breast cancer (31). Now, researchers are using Herceptin® to target potent 
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chemotherapeutics or toxins for breast cancer chemotherapy. Some of the antibodies being 
explored for treating leukemia may soon follow similar ‘carrier’ approaches.
Recently, lymphocyte function-associated antigen-1 (LFA-1), a primary cell adhesion 
molecule, has also been investigated for targeting nanoparticles to human leukemic cell line 
(30, 32). Lima et al. reported that certain leukemic cells expressed 5-fold more LFA-1 than 
normal leukocytes (32). Since LFA-1 is expressed only on leukocytes, it may be possible to 
also use LFA-1 as a target for drug carrier conjugated with LFA-1 ligands and perhaps to 
differentially target certain types of leukemic cells.
In leukemia, LFA-1 expression determines the clinical and biological behavior of lymphoid 
malignancies. In human lymphomas, differential LFA-1 expression is related to the different 
maturation stage, growth pattern, degree of clinical aggressiveness, and anatomic site of 
tumor in different types of leukemia (33). Ahsmann et al. have found the presence of LFA-1 
on tumor cells in low and medium grade malignant lymphomas but not on high grade 
malignant lymphomas(6). Since LFA-1 molecules play a role in cytolytic T cell-target cell 
conjugation, the absence of LFA-1 might contribute to an escape from 
immunosurveillance(6, 33–34). These trends suggest LFA-1 targeting may be preferred at 
earlier stages of cancer development.
Resting lymphocytes express the inactive form of LFA-1 but do not mediate firm adhesion 
to their ligands since the active form of LFA-1 can cause aggregation and clogging in blood 
vessels(10). The inactive form of LFA-1 is converted to the active conformational state by 
several stimuli such as chemokines and cytokines leading to a rapid increase in LFA-1 
function(35). In leukemia, some patients’ leukemic cells may express inactive integrins that 
are non-functional, some that are constitutively active and some that are inactive but 
regulated by cytokines or other stimuli(35–36).
POTENTIAL OF LFA-1 TARGETED NANOPARTICLES
Targeted drug delivery systems promise to expand the efficacy and decrease the potential 
toxic side effects of drugs by increasing their localization to specific organs, tissues or cells 
(37). To enhance the targeting of nanoparticles to specific cells or tissues, target-specific 
ligands must be linked to the nanoparticle surface (38). For targeted delivery to tumors, the 
cellular target often consists of a membrane-bound tumor-associated antigen (TAA) such as 
folate receptor, which is amplified in a wide variety of human tumors (39). Target-specific 
ligands that are linked to nanoparticles have been divided into classes based on the target 
receptors: (i) targets that are preferentially expressed on endothelial cells of tumor blood 
vessels (e.g. integrin-αvβ3), (ii) targets that are overexpressed on tumor cells (e.g. HER2 and 
disialoganglioside (GD2)), and (iii) lineage-specific targets that are expressed at the same 
level on tumor cells and on normal cells (e.g. CD19)(40).
Cyclic peptides derived from the binding domain of ICAM-1, domain 1, with LFA-1 may be 
conjugated to drugs or drug carriers for targeting LFA-1. Cyclic peptides (cIBL, cIBR, 
cIBC, CH4 and CH7) derived from residues 1–21 of ICAM-1 Domain 1 (N terminus) have 
been investigated for the inhibition of ICAM-1/LFA-1 interaction between T-cells and 
epithelial cells (41). cIBR peptide, cyclo(1,12)Pen PRGGSVLVTGC, showed the highest 
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affinity to the isolated LFA-1 receptor compared to cIBC and cIBL(42). cIBR peptide has 
also been shown to inhibit LFA-1/ICAM-1 interaction (43) and this peptide was internalized 
selectively in LFA-1 expressing T-cells (44). Recently, cIBR has been coupled to PLGA 
nanoparticles for targeting lymphoblastic leukemic T-cells (45). Here, the selective binding 
and internalization of cIBR peptide conjugated on PLGA nanoparticles were investigated in 
four different types of leukemic cell lines expressing different degree of LFA-1 expression. 
The specific binding of LFA-1 targeted nanoparticles was compared with untargeted 
nanoparticles. The specificity of this drug delivery system may be useful for treating certain 
types of leukemia typified by LFA-1 overexpression. Finally, these studies suggest that 
targeted nanoparticle therapies may represent a viable therapeutic approach for leukemia 
when considered within the context of current trends in targeted therapies reviewed here.
EXPERIMENTAL EVIDENCE OF LFA-1 TARGETED NANOPARTICLES
The correlation of LFA-1 expression and the binding degree of LFA-1 targeted 
nanoparticles were investigated as a promise for differently targeting leukemias typified by 
LFA-1 upregulation. First, PLGA nanoparticles were prepared by a solvent displacement 
method and cIBR peptide was conjugated on nanoparticles by carbodiimide chemistry (44). 
The mean diameter of NPs and cIBR-NPs were 178.9 ± 3.0 and 219.2 ± 10.1 nm, 
respectively (Table 1). A low polydispersity index was obtained from both formulations and 
indicated a narrow size distribution of the nanoparticle suspension. These colloids were 
consistently homogenous and stable. The zeta potentials of NPs and cIBR-NPs were 
observed to be −28.5 mV and −31.3 mV, respectively. The peptide density on the surface of 
nanoparticles after reaction was calculated assuming a normal Gussian particle size 
distribution (Table2).
The relative expressions of LFA-1 on four different types of human leukemic cell lines were 
determined by immunofluorescence using anti-LFA-1-FITC antibody. The results indicated 
that Molt-3 cells (lymphoblastic cell line) expressed significantly more LFA-1 compared to 
the other cell types. U937 (promonocytic cell line), HL-60 (promyeloblastic cell line) and 
Molt-4 (lymphoblastic cell line) showed steadily decreasing LFA-1 expression levels (Fig.
1). Then, cIBR-NPs and unconjugated NPs, both containing the fluorescent dye coumarin-6, 
were incubated with these cell lines and evaluated at several time intervals. Flow cytometry 
data indicated that the binding and internalization of cIBR-NPs in these four types of 
leukemic cell lines was significantly greater than untargeted NPs (p < 0.05 (Fig.2)), 
suggesting that cIBR was an effective targeting molecule when conjugated to a drug carrier. 
The binding of cIBR-NPs in these four types of leukemic cells was very fast and the 
fluorescence intensity of cIBR-NPs were significantly greater over time when compared to 
unconjugated NPs (Fig.3) .The rapid and specific binding of cIBR-NPs to LFA-1 on 
leukemic cells confirms previous reports (45). The uptake of cIBR-NPs in HL-60 and 
Molt-3 cells after 5, 30 and 60 minutes were similar (p > 0.05) but the fluorescence intensity 
increased with an incubation time of 90 min (p< 0.05 (Fig. 4)). In Molt-4, the fluorescence 
intensity generally increased slightly with incubation time (Fig. 4). After 30, 60 and 90 min, 
the binding of cIBR-NPs did not significantly increase in U937 suggesting that the cIBR-
NPs may have saturated LFA-1 molecules. Beyond 30 min, the curves showed a plateau 
effect (Fig. 4). Molt-3 cells had the highest degree of binding and internalization of cIBR-
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NPs compared to HL-60 and Molt-4 cells at all time points (Fig. 4). Among the leukemic 
cells, Molt-3 cells showed the highest expression of LFA-1 in this study. The binding of 
cIBR-NPs in this cell line was also the highest (Fig. 4). Taken cumulatively, the increased 
degree of LFA-1 expression corresponded to the greater degree of binding and 
internalization of cIBR-NPs.
The cellular uptake of the coumarin-6 encapsulated cIBR-NPs and NPs were visualized by 
fluorescence microscopy. Fluorescence intensity was found to be greater for cIBR-NPs 
compared to untargeted NPs, further substantiating that cIBR-NPs interact with leukemia 
cells to a greater extent than untargeted nanoparticles. The results also indicated that the 
fluorescence intensity of Molt-3 cells, which had the highest level of LFA-1 expression, was 
greater than the intensity of Molt-4 cells, HL-60 cells and U937 cells incubated with cIBR-
NPs (Fig.5). These results supported the cellular uptake of cIBR-NPs as determined by flow 
cytometry. Both analytical methods suggested that the level of LFA-1 expression 
corresponded to the degree of cellular uptake of cIBR-NPs.
In order to evaluate the effect of temperature on the ability of leukemic cell lines to 
endocytose nanoparticles, cell uptake experiments were performed at different temperatures 
(4°C and 37°C). The cIBR-NP cell uptake at 37°C was obviously higher compared to 
4°C(Fig. 6). The cIBR-NP uptake at 37°C were 1.2-,1.4-, 1.6- and 5.5-fold higher than at 
4°C for Molt-4 cells, HL-60 cells, U937 cells and Molt-3 cells, respectively. The results 
suggested that the uptake of cIBR-NPs was somewhat temperature dependent indicating 
some involvement of an energy-dependent endocytic mechanism for nanoparticle 
internalization (46).
The cytotoxicities of cIBR-NPs and NPs were determined using an established MTS assay. 
The particle concentration was varied from 15.6 μg/ml to 8.0 mg/ml which included the 
concentration of nanoparticles used in the binding and internalization studies(2.2 mg/ml). 
The percentage of cell growth inhibition was assayed by quantifying surviving cells after 24 
h incubation. Both nanoparticle formulations exhibited low cytotoxicity in the cell lines 
tested (Fig. 7). Results demonstrated that these drug carriers may be translatable due to low 
toxicity.
In this study, the specific targeting of surface-modified nanoparticles conjugated with cIBR 
peptide was determined using four types of leukemic cell lines which exhibited dramatically 
different LFA-1 expression levels. The binding and uptake of cIBR-NPs was then compared. 
Particle size and size distribution are important characteristics of these types of nanoparticle 
systems. Desai et al. found that 100 nm nanoparticles had a 2.5 fold greater uptake than 1 
μm microparticles, and 6 fold greater uptake than 10 μm microparticles in a Caco-2 cell line 
[33]. Others have also demonstrated that the smaller particles have relatively higher 
intracellular uptake. The particle size and size distribution (Table 1) confirmed that both 
cIBR and untargeted nanoparticles had small size and narrow size distribution. The surface 
charge of both nanoparticles were around −30 mV, which is sufficient to support NP 
stability since the surface charge prevents aggregation of particles (47).
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Several leukemia cell lines were used to identify differential targeting of cIBR-NP as a 
function of LFA-1 expression levels. Molt-3 and Molt-4 cell lines were originally derived 
from a patient with T-cell acute lymphoblastic leukemia (ALL). HL-60 cell line was derived 
from a single patient with acute promyelocytic leukemia (AML) and U937 cell line was 
established from a human diffuse histiocytic lymphoma. Studies of LFA-1 expression on 
these cell lines showed that Molt-3 exhibited the highest level of LFA-1 expression. The 
uptake of targeted nanoparticles by Molt-4, HL-60 and Molt-3 cells were time dependent, 
however, it was hypothesized that cIBR–NPs quickly bound to cells via a saturable 
mechanism followed by internalization at 30 and 60 min incubation (48). At 90 min, 
increased binding and uptake may be facilitated by presentation of recycled LFA-1 receptor 
(49). The binding of cIBR-NPs did not significantly increase in U937 after 30 min, perhaps 
due to the differentiation of U937 monocytes after PMA stimulation (50). Others have 
reported differentiation of this cell line where PMA produced changes in morphology, 
certain cytochemical enzymes and the expression of macrophage markers (51).
The binding and internalization of both nanoparticles by leukemia cell line were confirmed 
via fluorescecent microscopy. Micrographs showed that cIBR-NPs bound better than 
untargeted nanoparticles. The results also indicated that the fluorescence intensity of Molt-3 
cells, which had the highest level of LFA-1 expression, was greater than the intensity of 
Molt-4 cells, HL-60 cells and U937 cells incubated with cIBR-NPs. The very low 
fluorescent intensity of Molt-3 cells after incubation with cIBR-NPs at 4°C revealed that 
temperature has the most significant effect on the nanoparticle uptake of this cell line. To 
develop these types of targeted nanoparticles, identification of the different endocytic 
pathways involved will be critical. Additionally, the partial inhibition of nanoparticle uptake 
at low temperature (4°C) suggested that the internalization of the cIBR-NPs likely occurred 
via an energy dependent receptor-mediated endocytic process (45–46). Similar results have 
been reported when targeting ICAM-1 (52). The results of LFA-1 expression and cellular 
binding and internalization of nanoparticles revealed the relationship between the level of 
LFA-1 expression and the magnitude of nanoparticle binding and internalization. Molt-3 
cells, which showed the highest LFA-1 expression, also exhibited the greatest binding and 
internalization of cIBR-NPs. Hence, certain leukemic cells overexpressing LFA-1 may 
differentially bind and internalize cIBR-NPs thus improving the selectivity of encapsulated 
chemotherapeutics.
CONCLUSION
Future leukemia therapeutics must offer improved drug selectivity to improve efficacy and 
reduce side effects of potent chemotherapies. The current state-of-art for targeting LFA-1 
and other leukemia therapies were reviewed. Also, a brief study was presented to offer 
additional perspective regarding the potential use of nanoparticles for targeting potent 
leukemia drugs. cIBR-coupled PLGA nanoparticles targeting LFA-1 were studied to 
determine differential binding to four different types of leukemic cell line, Molt-4, HL-60, 
U937 and Molt-3 cells. The results of cellular uptake of cIBR-NPs from flow cytometry and 
fluorescence microscopy showed a significant increase in nanoparticle uptake in LFA-1 
expressing cells compared to untargeted nanoparticles. Studies also revealed a strong 
correlation between LFA-1 expression level and the binding and internalization of cIBR-
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NPs. Moreover, the cIBR-NPs were non-cytotoxic as targeted drug carriers to LFA-1 
expressing cells. These studies suggest that nanoparticles may be differentially targeted to 
surface markers on leukemic cells as a future targeted therapy.
EXPERIMENTAL PROCEDURES
Cell culture
Molt-3, Molt-4, HL-60 and U937 cell lines (American Type Culture Collection, VA, USA) 
were cultured in RPMI 1640 (Thermo Scientific HyQPAK, UT, USA) supplemented with 
10%(v/v) fetal bovine serum and 1%(v/v) penicillin-streptomycin (10,000 U/ml), in a 
humidified 37°C incubator with 5% CO2 atmosphere.
Preparation of PLGA Nanoparticles loading fluorescent dye
Poly(DL-lactic-coglycolic acid)(50:50) with terminal carboxylate group (inherent viscosity 
0.67dL/g, LACTEL Absorbable Polymers International, AL, USA) and coumarin-6 were 
dissolved in acetone and was slowly dropped into a stirred carboxylated Pluronic F-127 
(BASF the Chemical Company, USA). The excess coumarin-6 and carboxylated Pluronic 
F-127 were removed by dialysis against 0.2% mannitol solution. The size and zeta potential 
of nanoparticles were evaluated using dynamic laser light scattering (ZetaPALS, 
Brookhaven Instrument Inc.).
Conjugation of cIBR Peptide to PLGA-Nanoparticles
A carbodiimde reaction was utilized for the coupling reaction of cIBR peptide to surface of 
nanoparticles using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC, 
Thermo Fisher Scientific Inc., IL, USA) and N-hydroxysuccinimide(NHS, Thermo Fisher 
Scientific Inc., IL, USA) as coupling agents. The activated nanoparticles were coupled with 
cIBR peptides (170 μmole) for 12 h. To determine the density of cIBR peptide on NPs, 
unreacted peptide was quantified by gradient reverse phase HPLC (SHIMADZU) using a 
C18 column (Vydac® HPLC column Protein and Peptide C18 column).
LFA-1 Expression on Leukemic Cell Lines
Cells were treated with 0.4% Phorbol 12-myristate 13-acetate (PMA, Biomol International 
LP., PA, USA) for 48 h to stimulate LFA-1 on the cell membranes. AB serum were added in 
to the PMA activated leukemic cell lines (2×106 cells/ml) and incubated at 4°C for 10 min to 
block non–specific binding. Cells were then reacted with anti LFA-1-FITC at 4°C for 45 
min and washed three times with cold 0.1% BSA in PBS. The fluorescent intensity was 
determined by using a flow cytometer.
In vitro Cellular Binding and Internalization of Nanoparticles
PMA treated Molt-3, Molt-4, HL-60 and U937 cell lines (2×105 cells/well) were incubated 
with cIBR -NPs or NPs (2.2 mg/ml) at 37°C for 5, 30, 60 and 90 min and washed three 
times with cold 0.1% BSA in PBS before measuring the fluorescent intensity by flow 
cytometer.
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For microscopic study, cIBR-NPs or NPs (2.2 mg/ml) were incubated with each PMA pre-
treated cell lines (2×106 cells/ml) for 30 min at 37°C, 5% CO2. A Nikon Eclipse 80i 
microscope equipped for epifluorescence was used for cell observation. Micrographs were 
taken using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and analyzed by 
Metamorph, version 6.2 (Universal Imaging Corp., West Chester, PA).
Temperature Effect in Cellular Uptake of Nanoparticles
Four types of PMA treated leukemic cell lines (2×106 cells/ml) were incubated with cIBR-
NPs or NPs (2.2 mg/ml) for 15, 30, 45, and 60 min at 4°C and 37°C and washed three times 
with ice-cold PBS. The uptake of cIBR-NPs or NPs by cells was determined by flow 
cytometry.
Cytotoxicity of Nanoparticles
Cytotoxicity of cIBR-NPs and NPs was evaluated on all studied cell lines using the MTS 
assay. Cells (8×103 cells/well/100μl) were incubated with various concentrations of cIBR-
NPs or NPs for 24 h. After removing nanoparticles, fresh serum free RPMI 1640 and MTS 
were added. The plates were incubated for 4 h at 37°C. The quantity of formazan product 
was determined by the amount of 490 nm absorbance.
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ABBREVIATIONS
ALL Acute lymphoblastic leukemia
AML Acute myeloid leukemia
cIBR-NPs cIBR conjugated nanoparticles
CML Chronic myelogenous leukemia
EDC 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride
FLT3 FMS-like tyrosine kinase 3
GD2 Disialoganglioside
HER2 Human Epidermal growth factor Receptor 2
ICAM-1 Intercellular adhesion molecule-1
LFA-1 Lymphocyte function-associated antigen-1
mTOR Mammalian Target of Rapamycin Complex-1
NPs Nanoparticles
NHS N-hydroxysuccinimide
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PMA Phorbol 12-myristate 13-acetate
PML Progressive leukoencephalopathy
RHAMM/CD168 Receptor for hyaluronic acid mediated motility
TAA Tumor-associated antigen
WT1 Wilms’ tumor gene 1
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Relative expression of the adhesion molecule LFA-1 on leukemic cell lines. Data represent 
the mean ± S.D. from experiments performed in triplicate. *** indicates p< 0.001
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Binding and internalization of cIBR-NPs and NPs after incubation (37°C; 60 min) with 
Molt-4, HL-60, U937 and Molt-3 cells. The fluorescence of leukemic cells incubated with 
cIBR-NPs were significantly greater when compared to unconjugated NPs. Results are given 
as mean ± S.D. (n=3); * indicates p< 0.05 and ** indicates p< 0.01
Phongpradist et al. Page 14























The comparison of fluorescence intensity between cells incubated with serum free medium 
(white color), cells incubated with NPs (gray color) and cells incubated with cIBR-NPs 
(black color) for 5 min incubation. Data are given as mean ± S.D.(n=3); **** indicates p< 
0.0001
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Kinetic binding profiles of cellular binding of cIBR-NPs by human leukemic cell lines 
(Molt-4, HL-60, U937 and Molt-3) after incubation for 5, 30, 60 and 90 min. Data 
represents mean ± S.D.(n=3); * indicates p<0.05, ** indicates p<0.01 and *** indicates 
p<0.001
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Fluorescent micrographs of (A1) Molt-4 cells incubated with coumarin-6 loaded NPs, (A2) 
Molt-4 cells incubated with coumarin-6 loaded cIBR-NPs, (B1) HL-60 cells incubated with 
coumarin-6 loaded NPs, (B2) HL-60 cells incubated with coumarin-6 loaded cIBR-NPs, 
(C1) U937 cells incubated with coumarin-6 loaded NPs, (C2) U937 cells incubated with 
coumarin-6 loaded cIBR-NPs, (D1) Molt-3 cells incubated with coumarin-6 loaded NPs and 
(D2) Molt-3 cells incubated with coumarin-6 loaded cIBR-NPs. The white arrows indicate 
the binding of cIBR-NPs or NPs to leukemic cells. All images were captured at the 
magnitude of 10X and were normalized for variations in excitation light intensity.
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Effect of temperature on cellular binding and internalization of cIBR-NPs after 45 min 
incubation. Data are given as mean ± S.D.(n=3); *** indicates p<0.001 and **** indicates 
p<0.0001
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Cytotoxicity of cIBR-NPs and NPs in (A) Molt-4 cells, (B) HL-60 cells, (C) U937 cells and 
(D) Molt-3 cells.
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Table 1
Properties of nanoparticles.
Property Coumarin-6 loaded NP Coumarin-6 loaded cIBR-NP
Mean size (nm) 178.9 ± 3.0 219.2 ± 10.1
Polydispersity 0.099 ± 0.09 0.067 ± 0.06
Zeta potential value (mV) −28.5 ± 2.17 −31.3 ± 1.37
Values are given as mean ± S.D. (n=3)
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Table 2
Calculated cIBR density on PLGA nanoparticles.
Nanoparticle Size (nm) Total Surface Area(m2/g of PLGA) Density of cIBR (pmol/cm2)
cIBR-NP 219.2 0.0397 41.7 ± 2.4
Values are given as mean ± S.D. (n=3)
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